10-QPeriod: Q2 FY2020

UNITEDHEALTH GROUP INC Quarterly Report for Q2 Ended Jun 30, 2020

Filed August 3, 2020For Securities:UNH

Summary

UnitedHealth Group's Q2 2020 10-Q filing reveals a strong performance driven by the COVID-19 pandemic's impact on healthcare utilization. While total revenues saw a modest increase of 3% year-over-year to $62.1 billion, net earnings attributable to common shareholders surged by 102% to $6.6 billion, resulting in a diluted EPS of $6.91. This significant earnings growth was largely attributed to temporary deferrals of medical care by consumers, which substantially reduced medical costs for the UnitedHealthcare segment, boosting operating earnings. The Optum segment also demonstrated robust growth, with revenues increasing by 17% to $32.7 billion, driven by OptumHealth and OptumInsight. Despite some OptumRx script volume declines due to care deferrals, overall Optum performance remained strong. The company ended the quarter with substantial liquidity, evidenced by a significant increase in cash and cash equivalents and strong operating cash flows, reinforcing its financial stability amidst economic uncertainty.

Financial Highlights

55 data points
Beta

Revenue

$62.14B

87.9% Gross Margin

Net Income

$6.64B

10.7% Net Margin

EPS (Diluted)

$6.91

Total Assets

$192.48B

Cash & Equivalents

$22.33B

Free Cash Flow

$9.55B

Financial Statements
Beta
Revenue$62.14B
Cost of Revenue$7.50B
Gross Profit$54.64B
SG&A Expenses$10.00B
Operating Expenses$52.90B
Operating Income$9.24B
Interest Expense$430.00M
Net Income$6.64B
EPS (Basic)$6.99
EPS (Diluted)$6.91
Shares Outstanding (Basic)949.00M
Shares Outstanding (Diluted)960.00M

Key Highlights

  • 1Total revenues increased by 3% to $62.1 billion for the quarter ended June 30, 2020.
  • 2Net earnings attributable to UnitedHealth Group common shareholders more than doubled, increasing by 102% to $6.6 billion.
  • 3Diluted earnings per share (EPS) rose significantly to $6.91, a 102% increase year-over-year.
  • 4The UnitedHealthcare segment's earnings from operations saw a substantial 165% increase, primarily due to lower medical costs resulting from COVID-19 related care deferrals.
  • 5The Optum segment reported a 17% revenue increase to $32.7 billion, with strong growth in OptumHealth and OptumInsight.
  • 6Cash flows from operating activities were robust, totaling $12.9 billion for the six months ended June 30, 2020, a significant increase from the prior year.
  • 7The company declared a quarterly cash dividend of $1.25 per share, an increase from the previous year's rate.

Frequently Asked Questions

The COVID-19 pandemic had a dual impact. The temporary deferral of medical care by consumers led to significantly lower medical costs for UnitedHealthcare, boosting operating earnings. However, OptumRx experienced some decline in script volumes due to reduced care encounters. Overall, the net effect of these trends, particularly the reduction in medical costs, significantly benefited the company's net earnings.

While care deferrals led to favorable medical cost trends in Q2 2020, the company anticipates that as health system capacity normalizes and consumer demand for care increases, future medical costs may rise, potentially exceeding normal baselines in the latter half of the year. The company is monitoring health system capacity for potential volatility.

During the six months ended June 30, 2020, UnitedHealth Group repurchased $1.7 billion of its stock. In June 2020, the Board of Directors increased the quarterly cash dividend to an annual rate of $5.00 per share, up from $4.32 per share previously.

UnitedHealth Group maintains a strong liquidity position, with $22.3 billion in cash and cash equivalents as of June 30, 2020, of which $4.2 billion was available for general corporate use. The company also has access to significant revolving bank credit facilities. Operating cash flows were strong, providing substantial funds for operations, investments, and capital returns to shareholders.